GSHD · Goosehead Insurance, Inc. · Stock research

Current Thesis

The July binary is a month behind the tape and the re-rating has kept extending on no new information. Goosehead printed Q2 2026 after the close on 2026-07-22: total revenue $113.389M against $103.356M consensus, adjusted EPS $0.64 against $0.48, adjusted EBITDA $37.9M (+30% YoY) at a 33% margin, and a full-year organic revenue-growth band lifted to 12–19% from 10–19%. The last dated headline on the name is UBS raising its target to $72 on 2026-07-27. Since then the only public filings are founder-side unit conversions followed by sales. Price closed at $72.52 on 2026-08-21, against $66.29 on 2026-08-14 and $54.28 on 2026-07-17 — the session before the print. The leg being bought is unchanged: the end of a derate, with margin expansion arriving before revenue reacceleration. What changed in the last week is where price sits relative to the people who publish targets. The 2026-08-21 close is above UBS's $72 (2026-07-27), above the $72 Keefe, Bruyette & Woods cut to on 2026-07-23, and above the roughly $71 aggregator consensus struck across 17 analysts. The next company-generated number lands at the Q3 print, around late October.

Bullish and bearish views on Goosehead Insurance, Inc.

The model's bull view on Goosehead Insurance, Inc. (GSHD), in brief: Q2 2026 (2026-07-22): revenue $113.389M vs $103.356M consensus, adjusted EPS $0.64 vs $0.48. The bear view: Core revenue grew +10% to $95.6M in Q2 2026, down from +15% in Q1 2026, while total revenue grew 21%. Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-22): revenue $113.389M vs $103.356M consensus, adjusted EPS $0.64 vs $0.48. The move off that print has now been held for a month and extended, rather than round-tripped.
• Adjusted EBITDA $37.9M, +30% YoY, margin 33% — two points wider YoY. Operating leverage is showing up before any recurring-revenue reacceleration.
• FY2026 organic total-revenue growth guided to 12–19% at the print, floor raised from 10%; written-premium growth 12–20%. Management tied a second-half acceleration to improving client retention and new-business generation.
• Scale metrics compounding: total written premium $1.34B (+14%), policies in force ~2.1M (+15%), corporate sales agents 583 (+22% YoY) at 2026-06-30.
• Buyback executed well below current levels: 95,000 shares repurchased at a $40.95 average during Q2 2026, with $144.6M of authorization remaining at quarter-end.
• Succession is internal and dated: Mark Jones, Jr. Becomes CEO effective 2027-01-01, Mark Miller retiring 2026-12-31 — announced with the beat on 2026-07-22, not as a separate shock.
• Price is still 19.0% below the $89.49 52-week high as of the 2026-08-21 close, so the re-rating has not restored the prior peak.

Bear Case

• Core revenue grew +10% to $95.6M in Q2 2026, down from +15% in Q1 2026, while total revenue grew 21%. Contingent commissions supplied $15.7M against $4.5M a year earlier — a carrier-profitability-dependent line that does not compound on schedule.
• The franchise engine is close to static: franchise producers 2,190 (+5% YoY) versus corporate agents +22%. Growth is migrating to a headcount build the company funds itself.
• Client retention was 86% at Q2 2026. The guided second-half acceleration is explicitly conditioned on that number improving.
• The sell-side gap has closed and inverted. One aggregator shows a ~$71 average across 17 analysts (6 Buy / 6 Hold / 1 Sell, range $43–$125) against a 2026-08-21 close of $72.52; on 2026-07-17 the same construction implied a wide discount.
• Founder-side supply is arriving into the advance. A Form 144 filed 2026-08-13 covers 15,000 Class A shares, aggregate market value $983,250, through J.P. Morgan Securities. A Form 4 filed 2026-08-17 shows Serena Jones (10% owner and director) converting LLC units and Class B shares and selling 250 Class A at $67.50 on 2026-08-13, outside a Rule 10b5-1 plan. The pattern is older than this leg: on 2026-05-26 Mark and Robyn Jones and a family trust converted and sold 45,588 Class A at a $40.07 weighted average.
• Balance sheet is thin as a shock absorber: $23.7M cash and equivalents against $323.0M total notes payable at 2026-06-30.

Setup & Price Structure

The narrative is maturing. The dating is straightforward — the informational event was 2026-07-22, the last fresh sell-side action was 2026-07-27, and the move from $66.29 (2026-08-14) to $72.52 (2026-08-21) happened with no company headline and no filing other than insider conversions. Attention is not expanding; price is.

Observable positioning and crowding evidence, without a verdict attached:

• The 2026-08-21 close of $72.52 sits above the two highest post-print targets published on the name ($72 from UBS on 2026-07-27, $72 from KBW on 2026-07-23) and above the ~$71 aggregator consensus across 17 analysts.
• RSI(14) at 66.4 on 2026-08-21 — elevated, below the conventional 70 overbought marker.
• A three-month price change of +74.0% into 2026-08-21, with the stock still 19.0% under the $89.49 52-week high.
• Insider distribution is confirmed at the small end and noticed at the larger end: 250 shares sold at $67.50 on 2026-08-13 (Form 4, filed 2026-08-17) against a 15,000-share Rule 144 notice filed the same day. The gap between the notice and the confirmed sale is the open question — the notice runs three months.
• No earnings date inside the next 30 days, so there is no scheduled event to compress or resolve the move.

Structurally, the post-print shelf is the $66.29 area that held from late July into 2026-08-14; the pre-print reference is $54.28 (2026-07-17). The August leg above that shelf is the part with no fundamental news underneath it.

Catalyst Calendar (next 30 days)

• No scheduled company event between 2026-08-23 and 2026-09-22. Goosehead has not announced a Q3 date; the historical cadence places it around 2026-10-21 (est.), outside this window.
• ~2026-09-10 (est.) — climatological peak of the Atlantic hurricane season. Not a company event, but catastrophe severity feeds carrier underwriting profitability, which sets the contingent-commission pool that produced $15.7M in Q2 2026 versus $4.5M a year earlier.
• Through ~2026-11-11 — the three-month sale window opened by the 2026-08-13 Form 144 (15,000 Class A shares). Any further Form 4s inside it are dated evidence on whether founder-side supply keeps meeting this price.
• ~2026-10-21 (est.) — Q3 2026 print. First test of the 12–19% FY organic band and of whether core revenue holds the +10% Q2 pace as contingents normalize.

What Would Change Our Mind

The structure that matters is the August leg built above the $66.29 shelf on zero company news. Losing that leg entirely — a weekly close below $64 — would put price back inside the post-print consolidation and reframe the last month as a momentum overshoot rather than a durable re-rating; that is the gradeable break. Three non-price observables would do the same work more slowly. First, the Q3 print (~2026-10-21 est.) trimming the 12–19% organic band or the 12–20% written-premium band, or showing core revenue growth below the +10% recorded in Q2 2026 while contingent commissions revert toward the $4.5M prior-year level. Second, retention printing at or below 86% at Q3, which removes the mechanism management named for the second-half acceleration. Third, Form 4s completing the 15,000-share Rule 144 notice at prices above the ~$65.55 implied by its $983,250 aggregate value, alongside further target cuts in the shape of the KBW reduction to $72 on 2026-07-23. On the other side, a Q3 print that holds +10%-or-better core growth with contingents normalized would remove the central objection in this note, since the beat would then be recurring.

Correlation Notes

• Peer read-across runs to personal-lines and commercial brokers (BRO, AJG, MMC): the group trades on organic-growth prints and contingent-commission commentary, so a peer flagging softening contingents ahead of Goosehead's Q3 would be an early signal on the same line item.
• New-business attachment is levered to US home-purchase and mortgage-closing volume, since Goosehead's franchise and corporate agents originate heavily at closing. Slower existing-home turnover shows up in policies-in-force growth before it shows up in revenue — that link is inference from the business model, not a disclosed sensitivity.
• The contingent line couples the stock to catastrophe outcomes with a lag: a severe Atlantic season damages carrier profitability, which sets contingent payouts recognized in later quarters.
• As a sub-$3B-cap name that has moved +74.0% in three months, it carries small-cap index beta and is exposed to any unwind in the low-quality/high-beta rotation independent of its own numbers.
• Softening personal auto and homeowners rate levels compress commission per policy even when policy counts grow; premium growth of +14% at Q2 2026 against policies-in-force growth of +15% is where that pressure would appear first.